News

Communications chips maker Qorvo (NASDAQ: QRVO) reported Q1 CY2025 results topping the market’s revenue expectations, but sales fell by 7.6% year on year to $869.5 million. Guidance for next quarter’s revenue was optimistic at $775 million at the midpoint, 2.4% above analysts’ estimates. Its non-GAAP profit of $1.42 per share was 41.6% above analysts’ consensus estimates.

Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 132% in the afternoon session after the company announced plans to make it easier for its members to access Eli Lilly's FDA-approved weight loss drug Zepbound. Given the success of weight loss drugs with regulatory approval and the crackdown on knock-offs, expanding the distribution of Zepbound should accelerate adoption. Additionally, companies such as WeightWatchers should benefit from increased sales volume and greater cust

Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 132% in the afternoon session after the company announced plans to make it easier for its members to access Eli Lilly's FDA-approved weight loss drug Zepbound. Given the success of weight loss drugs with regulatory approval and the crackdown on knock-offs, expanding the distribution of Zepbound should accelerate adoption. Additionally, companies such as WeightWatchers should benefit from increased sales volume and greater cust

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 34.8% in the afternoon session after the company reported disappointing first-quarter 2025 earnings as sales fell below Wall Street's expectations. Another blemish was that while full-year revenue guidance was raised, full-year EBITDA guidance was maintained, signaling that profit margins for the year would be lower than initially expected. On the other hand, NeoGenomics beat analysts' EPS expectations, and its full-ye

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 34.8% in the afternoon session after the company reported disappointing first-quarter 2025 earnings as sales fell below Wall Street's expectations. Another blemish was that while full-year revenue guidance was raised, full-year EBITDA guidance was maintained, signaling that profit margins for the year would be lower than initially expected. On the other hand, NeoGenomics beat analysts' EPS expectations, and its full-ye

(Bloomberg) -- Oil dropped as the global trade war hurt the outlook for demand, with data indicating signs of strain in the US economy. Most Read from BloombergNew York City Transit System Chips Away at Subway Fare EvasionNYC’s Congestion Toll Raised $159 Million in the First QuarterThe Last Thing US Transit Agencies Should Do NowAt Bryn Mawr, a Monumental Plaza Traces the Steps of Black HistoryAt the National Public Housing Museum, an Embattled Idea Finds a HomeWest Texas Intermediate slipped 2

There's been a “fundamental shift” in the crypto landscape in the U.S., CEO Anthony Noto said on Wednesday.